303 related articles for article (PubMed ID: 31314805)
1. Stem cell enriched lipotransfer reverses the effects of fibrosis in systemic sclerosis.
Almadori A; Griffin M; Ryan CM; Hunt DF; Hansen E; Kumar R; Abraham DJ; Denton CP; Butler PEM
PLoS One; 2019; 14(7):e0218068. PubMed ID: 31314805
[TBL] [Abstract][Full Text] [Related]
2. Intrinsic Deregulation of Vascular Smooth Muscle and Myofibroblast Differentiation in Mesenchymal Stromal Cells from Patients with Systemic Sclerosis.
Hegner B; Schaub T; Catar R; Kusch A; Wagner P; Essin K; Lange C; Riemekasten G; Dragun D
PLoS One; 2016; 11(4):e0153101. PubMed ID: 27054717
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of human adipose derived stem cells in scleroderma in comparison to sex and age matched normal controls: implications for regenerative medicine.
Griffin M; Ryan CM; Pathan O; Abraham D; Denton CP; Butler PE
Stem Cell Res Ther; 2017 Feb; 8(1):23. PubMed ID: 28173869
[TBL] [Abstract][Full Text] [Related]
4. COA-Cl prevented TGF-β1-induced CTGF expression by Akt dephosphorylation in normal human dermal fibroblasts, and it attenuated skin fibrosis in mice models of systemic sclerosis.
Nakai K; Karita S; Igarashi J; Tsukamoto I; Hirano K; Kubota Y
J Dermatol Sci; 2019 Apr; 94(1):205-212. PubMed ID: 30954335
[TBL] [Abstract][Full Text] [Related]
5. Feasibility study of stem-cell enriched autologous lipotransfer to treat oro-facial fibrosis in systemic sclerosis (Sys-Stem): Protocol for open-label randomised controlled trial.
Jeon FHK; Griffin M; Denton CP; Butler PEM
Int J Surg Protoc; 2020; 23():6-10. PubMed ID: 32803023
[TBL] [Abstract][Full Text] [Related]
6. The fibrotic phenotype of systemic sclerosis fibroblasts varies with disease duration and severity of skin involvement: reconstitution of skin fibrosis development using a tissue engineering approach.
Corriveau MP; Boufaied I; Lessard J; Chabaud S; Senécal JL; Grodzicky T; Chartier S; Raymond Y; Moulin VJ
J Pathol; 2009 Mar; 217(4):534-42. PubMed ID: 19086038
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional profiling of the scleroderma fibroblast reveals a potential role for connective tissue growth factor (CTGF) in pathological fibrosis.
Leask A
Keio J Med; 2004 Jun; 53(2):74-7. PubMed ID: 15247510
[TBL] [Abstract][Full Text] [Related]
8. Metabolic reprogramming of glycolysis and glutamine metabolism are key events in myofibroblast transition in systemic sclerosis pathogenesis.
Henderson J; Duffy L; Stratton R; Ford D; O'Reilly S
J Cell Mol Med; 2020 Dec; 24(23):14026-14038. PubMed ID: 33140521
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Pathological Phenotype of Hypertrophic Scar Fibroblasts Via Coculture with Adipose-Derived Stem Cells.
Deng J; Shi Y; Gao Z; Zhang W; Wu X; Cao W; Liu W
Tissue Eng Part A; 2018 Mar; 24(5-6):382-393. PubMed ID: 28562226
[TBL] [Abstract][Full Text] [Related]
10. Retinoic acids exhibit anti-fibrotic activity through the inhibition of 5-lipoxygenase expression in scleroderma fibroblasts.
Xiao R; Yoshida N; Higashi Y; Lu QJ; Fukushige T; Kanzaki T; Kanekura T
J Dermatol; 2011 Apr; 38(4):345-53. PubMed ID: 21352343
[TBL] [Abstract][Full Text] [Related]
11. 5-HT
Chaturvedi S; Misra DP; Prasad N; Rastogi K; Singh H; Rai MK; Agarwal V
Int J Rheum Dis; 2018 Dec; 21(12):2128-2138. PubMed ID: 30207074
[TBL] [Abstract][Full Text] [Related]
12. Induction of matrix metalloproteinase-1 by small interfering RNA targeting connective tissue growth factor in dermal fibroblasts from patients with systemic sclerosis.
Ishibuchi H; Abe M; Yokoyama Y; Ishikawa O
Exp Dermatol; 2010 Aug; 19(8):e111-6. PubMed ID: 20653770
[TBL] [Abstract][Full Text] [Related]
13. Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate.
Dooley A; Shi-Wen X; Aden N; Tranah T; Desai N; Denton CP; Abraham DJ; Bruckdorfer R
Rheumatology (Oxford); 2010 Nov; 49(11):2024-36. PubMed ID: 20627968
[TBL] [Abstract][Full Text] [Related]
14. Attenuation of fibrosis with selective inhibition of c-Abl by siRNA in systemic sclerosis dermal fibroblasts.
Karimizadeh E; Motamed N; Mahmoudi M; Jafarinejad-Farsangi S; Jamshidi A; Faridani H; Gharibdoost F
Arch Dermatol Res; 2015 Mar; 307(2):135-42. PubMed ID: 25527259
[TBL] [Abstract][Full Text] [Related]
15. Blockade of PDGF Receptors by Crenolanib Has Therapeutic Effect in Patient Fibroblasts and in Preclinical Models of Systemic Sclerosis.
Makino K; Makino T; Stawski L; Mantero JC; Lafyatis R; Simms R; Trojanowska M
J Invest Dermatol; 2017 Aug; 137(8):1671-1681. PubMed ID: 28433542
[TBL] [Abstract][Full Text] [Related]
16. Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis.
Aden N; Nuttall A; Shiwen X; de Winter P; Leask A; Black CM; Denton CP; Abraham DJ; Stratton RJ
J Invest Dermatol; 2010 Sep; 130(9):2191-200. PubMed ID: 20445556
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of hepatocyte growth factor receptor in scleroderma dermal fibroblasts is caused by autocrine transforming growth factor β signaling.
Kajihara I; Jinnin M; Makino T; Masuguchi S; Sakai K; Fukushima S; Maruo K; Inoue Y; Ihn H
Biosci Trends; 2012 Jun; 6(3):136-42. PubMed ID: 22890162
[TBL] [Abstract][Full Text] [Related]
18. Connective tissue growth factor causes persistent proalpha2(I) collagen gene expression induced by transforming growth factor-beta in a mouse fibrosis model.
Chujo S; Shirasaki F; Kawara S; Inagaki Y; Kinbara T; Inaoki M; Takigawa M; Takehara K
J Cell Physiol; 2005 May; 203(2):447-56. PubMed ID: 15605379
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia induces expression of connective tissue growth factor in scleroderma skin fibroblasts.
Hong KH; Yoo SA; Kang SS; Choi JJ; Kim WU; Cho CS
Clin Exp Immunol; 2006 Nov; 146(2):362-70. PubMed ID: 17034590
[TBL] [Abstract][Full Text] [Related]
20. Extracellular SPARC cooperates with TGF-β signalling to induce pro-fibrotic activation of systemic sclerosis patient dermal fibroblasts.
Carvalheiro T; Malvar Fernández B; Ottria A; Giovannone B; Marut W; Reedquist KA; Garcia S; Radstake TR
Rheumatology (Oxford); 2020 Sep; 59(9):2258-2263. PubMed ID: 31840182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
